- Home
- AMGN vs PANW Comparison
AMGN vs PANW Comparison
Compare AMGN & PANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- PANW
- Stock Information
- Founded
- AMGN 1980
- PANW 2005
- Country
- AMGN United States
- PANW United States
- Employees
- AMGN N/A
- PANW N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- PANW Computer peripheral equipment
- Sector
- AMGN Health Care
- PANW Technology
- Exchange
- AMGN Nasdaq
- PANW Nasdaq
- Market Cap
- AMGN 150.8B
- PANW 124.9B
- IPO Year
- AMGN N/A
- PANW 2012
- Fundamental
- Price
- AMGN $292.00
- PANW $218.27
- Analyst Decision
- AMGN Hold
- PANW Buy
- Analyst Count
- AMGN 15
- PANW 43
- Target Price
- AMGN $313.57
- PANW $216.33
- AVG Volume (30 Days)
- AMGN 2.0M
- PANW 4.6M
- Earning Date
- AMGN 11-04-2025
- PANW 11-19-2025
- Dividend Yield
- AMGN 3.26%
- PANW N/A
- EPS Growth
- AMGN 110.88
- PANW N/A
- EPS
- AMGN 12.23
- PANW 1.60
- Revenue
- AMGN $34,917,000,000.00
- PANW $9,221,500,000.00
- Revenue This Year
- AMGN $8.90
- PANW $16.29
- Revenue Next Year
- AMGN $1.79
- PANW $13.42
- P/E Ratio
- AMGN $23.88
- PANW $136.42
- Revenue Growth
- AMGN 12.88
- PANW 14.87
- 52 Week Low
- AMGN $253.30
- PANW $144.15
- 52 Week High
- AMGN $335.88
- PANW $223.61
- Technical
- Relative Strength Index (RSI)
- AMGN 50.00
- PANW 61.36
- Support Level
- AMGN $293.14
- PANW $216.00
- Resistance Level
- AMGN $294.81
- PANW $223.61
- Average True Range (ATR)
- AMGN 5.57
- PANW 4.22
- MACD
- AMGN -0.94
- PANW 0.16
- Stochastic Oscillator
- AMGN 23.99
- PANW 73.60
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.